Azra H Ligon

List of Publications by Year in Descending Order

93 papers	16,056 citations	46 h-index	97 g-index
97 ext. papers	18,627 ext. citations	8.6 avg, IF	5.57 L-index

#	Paper	IF	Citations
93	LGG-06. Selumetinib in pediatric patients with non-neurofibromatosis type 1-associated, non-optic pathway (OPG) and non-pilocytic recurrent/progressive low-grade glioma harboring BRAFV600E mutation or BRAF-KIAA1549 fusion: a multicenter prospective Pediatric Brain Tumor Consortium (PBTC) Phase 2 trial. *Neuro-Oncology*, **2022**, 24, i88-i88	1	0
92	Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. *Modern Pathology*, **2021**, 34, 603-612	9.8	4
91	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. *Blood*, **2021**, 137, 1353-1364	2.2	11
90	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. *Clinical Cancer Research*, **2021**, 27, 1695-1705	12.9	9
89	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. *Neuro-Oncology*, **2021**, 23, 1777-1788	1	17
88	A Molecularly Integrated Grade for Meningioma. *Neuro-Oncology*, **2021**,	1	7
87	A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. *American Journal of Surgical Pathology*, **2020**, 44, 922-933	6.7	59
86	Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. *Cancer Genetics*, **2020**, 243, 19-47	2.3	1
85	Molecular and clinicopathologic features of gliomas harboring NTRK fusions. *Acta Neuropathologica Communications*, **2020**, 8, 107	7.3	36
84	Characterization of molecular signatures of supratentorial ependymomas. *Modern Pathology*, **2020**, 33, 47-56	9.8	7
83	Mechanisms and therapeutic implications of hypermutation in gliomas. *Nature*, **2020**, 580, 517-523	50.4	172
82	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. *American Journal of Clinical Pathology*, **2019**, 152, 97-108	1.9	17
81	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1011-1022	21.7	182
80	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. *Journal of Clinical Oncology*, **2019**, 37, 1997-2007	2.2	110
79	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. *Neuro-Oncology*, **2019**, 21, ii30-ii30	1	2
78	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. *Journal of Clinical Oncology*, **2019**, 37, 741-750	2.2	64
77	Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. *Journal of Clinical Oncology*, **2019**, 37, 481-489	2.2	173

76	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. *Journal of Clinical Oncology*, **2019**, 37, 3291-3299	2.2	116
75	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. *Cureus*, **2019**, 11, e4726	1.2	1
74	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. *Blood*, **2018**, 132, 228-228	2.2	11
73	Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma. *Blood*, **2018**, 132, 1579-1579	2.2	2
72	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2018**, 36, 942-950	2.2	175
71	LTBK-01. UPDATES ON THE PHASE II AND RE-TREATMENT STUDY OF AZD6244 (SELUMETINIB) FOR CHILDREN WITH RECURRENT OR REFRACTORY PEDIATRIC LOW GRADE GLIOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. *Neuro-Oncology*, **2018**, 20, i214-i214	1	0
70	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. *Neuro-Oncology*, **2017**, 19, 986-996	1	39
69	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 751-758	5	206
68	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. *Neuro-Oncology*, **2017**, 19, 908-917	1	14
67	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology*, **2017**, 19, 535-545	1	60
66	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. *Current Genetic Medicine Reports*, **2017**, 5, 117-124	2.2	2
65	Landscape of Genomic Alterations in Pituitary Adenomas. *Clinical Cancer Research*, **2017**, 23, 1841-1851	12.9	64
64	A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.. *Journal of Clinical Oncology*, **2017**, 35, 10504-10504	2.2	10
63	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1283-94	21.7	643
62	Genomic characterization of recurrent high-grade astroblastoma. *Cancer Genetics*, **2016**, 209, 321-30	2.3	15
61	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. *Cancer Immunology Research*, **2016**, 4, 910-916	12.5	118
60	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. *Journal of Clinical Oncology*, **2016**, 34, 2698-704	2.2	677
59	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. *Nature Medicine*, **2016**, 22, 723-6	50.5	76

58	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. *World Neurosurgery*, **2016**, 85, 96-105	2.1	11
57	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. *Nature Genetics*, **2016**, 48, 273-82	36.3	154
56	Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. *Neuro-Oncology*, **2016**, 18, 649-55	1	144
55	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. *JAMA Oncology*, **2016**, 2, 518-22	13.4	95
54	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. *Neuro-Oncology*, **2016**, 18, 269-74	1	47
53	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. *Clinical Cancer Research*, **2016**, 22, 1185-96	12.9	54
52	Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). *Blood*, **2016**, 128, 2923-2923	2.2	4
51	Institutional implementation of clinical tumor profiling on an unselected cancer population. *JCI Insight*, **2016**, 1, e87062	9.9	245
50	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. *Diagnostic Pathology*, **2016**, 11, 13	3	8
49	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *Journal of Clinical Oncology*, **2016**, 34, 2690-7	2.2	472
48	Targetable genetic features of primary testicular and primary central nervous system lymphomas. *Blood*, **2016**, 127, 869-81	2.2	317
47	ARID1A and TERT promoter mutations in dedifferentiated meningioma. *Cancer Genetics*, **2015**, 208, 345-50	2.9	57
46	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. *Neuro-Oncology*, **2015**, 17, 1344-55	1	39
45	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *New England Journal of Medicine*, **2015**, 372, 311-9	59.2	2513
44	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. *Neuro-Oncology*, **2015**, 17, 1486-96	1	33
43	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. *Blood*, **2015**, 126, 176-176	2.2	1
42	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. *Oncotarget*, **2014**, 5, 10596-606	3.3	46
41	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clinical Cancer Research*, **2014**, 20, 1873-83	12.9	38

40	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. *Nature Genetics*, **2014**, 46, 462-6	36.3	296
39	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. *Neuro-Oncology*, **2014**, 16, 567-78	1	110
38	EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. *Cancer Discovery*, **2014**, 4, 956-71	24.4	199
37	Optic nerve glioma: case series with review of clinical, radiologic, molecular, and histopathologic characteristics. *Ophthalmic Plastic and Reconstructive Surgery*, **2014**, 30, 372-6	1.4	7
36	Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. *Blood*, **2014**, 124, 289-289	2.2	7
35	Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. *Blood*, **2014**, 124, 291-291	2.2	79
34	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. *Oncotarget*, **2014**, 5, 8083-92	3.3	46
33	Complex cytogenetic rearrangements at the DURS1 locus in syndromic Duane retraction syndrome. *Clinical Case Reports (discontinued)*, **2013**, 1, 30	0.7	2
32	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 8188-93	11.5	156
31	DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. *PLoS ONE*, **2012**, 7, e38881	3.7	24
30	BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. *Journal of Neuropathology and Experimental Neurology*, **2012**, 71, 789-94	3.1	51
29	Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2011**, Appendix 1, 1D	3.2	
28	BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. *PLoS ONE*, **2011**, 6, e17948	3.7	228
27	Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. *Nature Genetics*, **2011**, 43, 869-74	36.3	788
26	Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. *Journal of Molecular Diagnostics*, **2011**, 13, 669-77	5.1	69
25	The landscape of somatic copy-number alteration across human cancers. *Nature*, **2010**, 463, 899-905	50.4	2590
24	Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. *Neoplasia*, **2010**, 12, 161-72	6.4	46
23	Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. *American Journal of Pathology*, **2010**, 176, 1901-13	5.8	53

22	Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. *Journal of Clinical Oncology*, **2010**, 28, 835-40	2.2	297
21	Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2010**, Appendix 1, 1D.13	3.23	
20	Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. *Clinical Cancer Research*, **2009**, 15, 6430-7	12.9	72
19	CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. *Nature*, **2008**, 455, 547-51	50.4	519
18	Characterization of apparently balanced chromosomal rearrangements from the developmental genome anatomy project. *American Journal of Human Genetics*, **2008**, 82, 712-22	11	84
17	Candidate loci for Zimmermann-Laband syndrome at 3p14.3. *American Journal of Medical Genetics, Part A*, **2007**, 143A, 107-11	2.5	15
16	Disruption of a synaptotagmin (SYT14) associated with neurodevelopmental abnormalities. *American Journal of Medical Genetics, Part A*, **2007**, 143A, 558-63	2.5	13
15	NFIA haploinsufficiency is associated with a CNS malformation syndrome and urinary tract defects. *PLoS Genetics*, **2007**, 3, e80	6	80
14	Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. *American Journal of Human Genetics*, **2007**, 80, 792-9	11	33
13	Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. *American Journal of Human Genetics*, **2005**, 76, 340-8	11	103
12	Reporting of diagnostic cytogenetic results. *Current Protocols in Human Genetics*, **2004**, Appendix 1, Appendix 1D	3.2	
11	PCOLCE deletion and expression analyses in uterine leiomyomata. *Cancer Genetics and Cytogenetics* , **2002**, 137, 133-7		16
10	Dysregulation of HMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14 **2000**, 27, 209-215		28
9	Genetics of uterine leiomyomata. *Genes Chromosomes and Cancer*, **2000**, 28, 235-245	5	97
8	Identification of female carriers for Duchenne and Becker muscular dystrophies using a FISH-based approach. *European Journal of Human Genetics*, **2000**, 8, 293-8	5.3	20
7	Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. *Cancer Genetics and Cytogenetics*, **1999**, 114, 9-16		45
6	Gene for multiple exostoses (EXT2) maps to 11(p11.2p12) and is deleted in patients with a contiguous gene syndrome. *American Journal of Medical Genetics Part A*, **1998**, 75, 538-40		21
5	ORC5L, a new member of the human origin recognition complex, is deleted in uterine leiomyomas and malignant myeloid diseases. *Journal of Biological Chemistry*, **1998**, 273, 27137-45	5.4	59

4	Differentially expressed gene products in glioblastoma cells suppressed for tumorigenicity. *Journal of NeuroVirology*, **1998**, 4, 217-26	3.9	4
3	Simultaneous, multilocus FISH analysis for detection of microdeletions in the diagnostic evaluation of developmental delay and mental retardation. *American Journal of Human Genetics*, **1997**, 61, 51-9	11	36
2	Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. *Nature Genetics*, **1997**, 15, 356-62	36.3	2377
1	Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. *Genes Chromosomes and Cancer*, **1997**, 20, 260-267	5	6